Intersect ENT News Releases http://ir.intersectent.com/ Intersect ENT News Releases en Intersect ENT Reports First Quarter 2019 Results http://ir.intersectent.com/news-releases/news-release-details/intersect-ent-reports-first-quarter-2019-results MENLO PARK, Calif. --(BUSINESS WIRE)--May 6, 2019-- Intersect ENT ® , Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2019 . Mon, 06 May 2019 16:06:00 -0400 Intersect ENT News Releases 9351 Intersect ENT to Present at the Bank of America Merrill Lynch 2019 Health Care Conference http://ir.intersectent.com/news-releases/news-release-details/intersect-ent-present-bank-america-merrill-lynch-2019-health MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 25, 2019-- Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will participate in the 2019 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14, 2019 at the Encore Hotel in Las Vegas , including a Q&A session at 1:40 p.m. Thu, 25 Apr 2019 16:05:00 -0400 Intersect ENT News Releases 9321 Intersect ENT to Report First Quarter 2019 Financial Results http://ir.intersectent.com/news-releases/news-release-details/intersect-ent-report-first-quarter-2019-financial-results MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 23, 2019-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release first quarter financial results on May 6, 2019 . Tue, 23 Apr 2019 16:13:00 -0400 Intersect ENT News Releases 9306 Intersect ENT Reports Fourth Quarter and Full Year 2018 Results http://ir.intersectent.com/news-releases/news-release-details/intersect-ent-reports-fourth-quarter-and-full-year-2018-results ENCORE Clinical Study Completed, Primary Endpoints Met MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 25, 2019-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth Mon, 25 Feb 2019 16:05:00 -0500 Intersect ENT News Releases 9246 Intersect ENT to Present at the 8th Annual SVB Leerink Global Healthcare Conference http://ir.intersectent.com/news-releases/news-release-details/intersect-ent-present-8th-annual-svb-leerink-global-healthcare MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 12, 2019-- Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at the Lotte New York Palace in New York City , and will present in a Tue, 12 Feb 2019 16:05:00 -0500 Intersect ENT News Releases 9216 Intersect ENT to Report Fourth Quarter and Year 2018 Financial Results http://ir.intersectent.com/news-releases/news-release-details/intersect-ent-report-fourth-quarter-and-year-2018-financial MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 11, 2019-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release fourth quarter and year 2018 financial results on February 25, 2019 . Mon, 11 Feb 2019 16:05:00 -0500 Intersect ENT News Releases 9201 Intersect ENT Reports Preliminary Fourth Quarter and Full Year 2018 Revenue http://ir.intersectent.com/news-releases/news-release-details/intersect-ent-reports-preliminary-fourth-quarter-and-full-year MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 7, 2019-- Intersect ENT, Inc.  (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for the fourth quarter and full year ended  December 31, Mon, 07 Jan 2019 08:00:00 -0500 Intersect ENT News Releases 9111 Intersect ENT Announces First Patient Enrolled in ASCEND Study of Investigational Drug-Coated Sinus Balloon http://ir.intersectent.com/news-releases/news-release-details/intersect-ent-announces-first-patient-enrolled-ascend-study Innovative Drug-Device Combination Will Leverage Company’s Expertise in Localized Drug Delivery MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 17, 2018-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the Mon, 17 Dec 2018 08:00:00 -0500 Intersect ENT News Releases 9066 Intersect ENT to Present at the 37th Annual J.P. Morgan Healthcare Conference http://ir.intersectent.com/news-releases/news-release-details/intersect-ent-present-37th-annual-jp-morgan-healthcare MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 11, 2018-- Intersect ENT, Inc. (Nasdaq: XENT ), today announced that management will participate in the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at the Westin St. Francis Hotel in San Francisco , and will present at 4:30 Tue, 11 Dec 2018 16:05:00 -0500 Intersect ENT News Releases 9056 Intersect ENT Announces Publication of Pooled Analysis of Steroid Releasing Implants in Patients Following Frontal Sinus Surgery http://ir.intersectent.com/news-releases/news-release-details/intersect-ent-announces-publication-pooled-analysis-steroid MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 15, 2018-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced publication of a pooled analysis in the International Forum of Allergy & Rhinology , the official Thu, 15 Nov 2018 16:06:00 -0500 Intersect ENT News Releases 9046